Relugolix Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Relugolix comprises 54 peer-reviewed publications across 15 journals, 11 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Leiomyoma, Eunuchism, Prostatic Neoplasms, and Endometriosis. Most recent publication: Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial., JAMA Cardiol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group.
    Van den Bosch T, Dueholm M, Leone FP, et al. · Ultrasound Obstet Gynecol · 2016
    PubMed: PMID 25652685 · NCT06953076 (MySaturn) · Leiomyoma
  2. Minimum training recommendations for the practice of medical ultrasound.
    Education and Practical Standards Committee, European Federation of Societies for Ultrasound in Medicine and Biology · Ultraschall Med · 2006
    PubMed: PMID 16508866 · NCT06953076 (MySaturn) · Leiomyoma
  3. Uterine Fibroids: Diagnosis and Treatment.
    De La Cruz MS, Buchanan EM · Am Fam Physician · 2017
    PubMed: PMID 28084714 · NCT06953076 (MySaturn) · Leiomyoma
  4. A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd And mRi study.
    Ciccarone F, Biscione A, Robba E, et al. · Am J Obstet Gynecol · 2024
    PubMed: PMID 39084498 · NCT06953076 (MySaturn) · Leiomyoma
  5. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. · Am J Obstet Gynecol · 2023
    PubMed: PMID 37666383 · NCT06953076 (MySaturn) · Leiomyoma
  6. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
    Al-Hendy A, Lukes AS, Poindexter AN, et al. · Obstet Gynecol · 2022
    PubMed: PMID 36357960 · NCT06953076 (MySaturn) · Leiomyoma
  7. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A, Lukes AS, Poindexter AN, et al. · N Engl J Med · 2021
    PubMed: PMID 33596357 · NCT06953076 (MySaturn) · Leiomyoma
  8. Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.
    Patel SA, Yadalam AK, van Assen M, et al. · JAMA Cardiol · 2026
    PubMed: PMID 41706486 · NCT05320406 (REVELUTION) · Prostatic Neoplasms

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02655224LeiomyomaPercentage of Participants With a Maximum NRS Score of 1 or Less During the 28 Days Before the Final Dose of Study Drug
For 28 days before the final dose of study drug (up to Week 12)
Placebo3.1 percentage of participants
Relugolix 40 mg57.6 percentage of participants
NCT02655237LeiomyomaPercentage of Participants With Total PBAC Score of <10 From Week 6 to 12
Week 6 to 12
Leuprorelin 1.88 mg or 3.75 mg83.1 percentage of participants
Relugolix 40 mg82.2 percentage of participants
NCT03049735LeiomyomaPercentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA
From Baseline up to last 35 days of treatment (up to Week 24)
Placebo (Group C)18.9 Percentage of participants
Relugolix Plus E2/NETA (Group A)73.4 Percentage of participants
NCT03085095
HERO
Prostatic NeoplasmsSustained Castration Rate
From Week 5 Day 1 (Day 29) to Week 49 Day 1 (Day 337)
Leuprolide Acetate88.8 percentage of participants
Relugolix96.7 percentage of participants
NCT03103087LeiomyomaPercentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA
From Baseline up to the last 35 days of treatment (up to Week 24)
Placebo (Group C)14.73 Percentage of participants
Relugolix Plus E2/NETA (Group A)71.2 Percentage of participants
NCT03412890LeiomyomaPercentage Of Participants Who Achieved Or Maintained An MBL Volume Of <80 Milliliters (mL) And At Least A 50% Reduction From Baseline MBL Volume At Week 52/End Of Treatment
Week 52/End of Treatment
Placebo (Group C)75.00 percentage of participants
Relugolix Plus Delayed E2/NETA (Group B)79.87 percentage of participants
Relugolix Plus E2/NETA (Group A)86.50 percentage of participants
NCT03654274EndometriosisPercentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 104
Week 104
Placebo (Group C)80.4 percentage of participants
Relugolix Plus Delayed E2/NETA (Group B)83.0 percentage of participants
Relugolix Plus E2/NETA (Group A)84.8 percentage of participants
NCT03654274EndometriosisPercentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52
Week 52
Placebo (Group C)75.6 percentage of participants
Relugolix Plus Delayed E2/NETA (Group B)82.2 percentage of participants
Relugolix Plus E2/NETA (Group A)84.8 percentage of participants
NCT03654274EndometriosisPercentage Of Participants Who Meet The NMPP Responder Criteria At Week 104
Week 104
Placebo (Group C)73.1 percentage of participants
Relugolix Plus Delayed E2/NETA (Group B)71.7 percentage of participants
Relugolix Plus E2/NETA (Group A)75.8 percentage of participants
NCT03654274EndometriosisPercentage Of Participants Who Meet The NMPP Responder Criteria At Week 52
Week 52
Placebo (Group C)68.0 percentage of participants
Relugolix Plus Delayed E2/NETA (Group B)70.4 percentage of participants
Relugolix Plus E2/NETA (Group A)73.6 percentage of participants
NCT03751124LeiomyomaPercentage Of Participants Who Maintained MBL Volume Of <80 Milliliters (mL) At Week 76 During The Randomized Treatment Period
Week 52/Baseline up to Week 76
Placebo (Group B)15.08 percentage of participants
Relugolix Plus E2/NETA (Group A)78.43 percentage of participants

Publications by year

1972–2026: 54 publications.

1972
1
1974
1
1996
2
1997
3
2000
1
2001
1
2005
1
2006
1
2009
1
2016
2
2017
1
2018
2
2019
1
2020
3
2021
1
2022
8
2023
11
2024
8
2025
3
2026
2

Publications by indication

Leiomyoma (17)

  • Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2.
    Fertil Steril · 2025 · PMID 40320117 · NCT03103087
  • A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd And mRi study.
    Am J Obstet Gynecol · 2024 · PMID 39084498 · NCT06953076
  • A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy.
    Pain Manag · 2024 · PMID 39466126 · NCT03049735
  • Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Am J Obstet Gynecol · 2024 · PMID 37863160 · NCT03049735
  • LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Am J Obstet Gynecol · 2023 · PMID 37666383 · NCT06953076

Eunuchism (16)

  • Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition.
    Drug Metab Dispos · 2023 · PMID 36623880 · NCT06312761
  • Testosterone Replacement Therapy in Hypogonadal Men.
    Endocrinol Metab Clin North Am · 2022 · PMID 35216722 · NCT06312761
  • A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men.
    Ther Adv Urol · 2022 · PMID 32655691 · NCT06312761
  • Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.
    Drug Metab Dispos · 2018 · PMID 29602798 · NCT06312761
  • Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
    J Clin Endocrinol Metab · 2016 · PMID 26502357 · NCT06312761

Prostatic Neoplasms (9)

  • Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.
    JAMA Cardiol · 2026 · PMID 41706486 · NCT05320406
  • Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration.
    Adv Ther · 2025 · PMID 41174189 · NCT06462014
  • Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
    Future Oncol · 2024 · PMID 38488039 · NCT05467176
  • Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    J Urol · 2024 · PMID 39088398 · NCT04523207
  • Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    J Urol · 2024 · PMID 38421243 · NCT04423211

Endometriosis (6)

  • Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
    Hum Reprod · 2024 · PMID 38243752 · NCT03654274
  • Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
    Fertil Steril · 2024 · PMID 38906210 · NCT03654274
  • Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study.
    Int J Womens Health · 2023 · PMID 37283994 · NCT03204331
  • A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
    Pain Manag · 2023 · PMID 37982388 · NCT03204318
  • Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Lancet · 2022 · PMID 35717987 · NCT03204331

Pelvic Pain (2)

  • Cortical mechanisms of visual hypersensitivity in women at risk for chronic pelvic pain.
    Pain · 2022 · PMID 34510138 · NCT06279195
  • Cine MRI during spontaneous cramps in women with menstrual pain.
    Am J Obstet Gynecol · 2018 · PMID 29409786 · NCT06279195

Neoplasm, Residual (1)

  • Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.
    BMJ Open · 2026 · PMID 42031503 · NCT06130995

Publications by journal

Trial-results highlights

Clinical trials have investigated Relugolix across several conditions. For uterine leiomyoma, also known as uterine fibroids, multiple studies assessed its effects. In NCT02655224, 57.6% of participants in the Relugolix 40 mg arm achieved a maximum NRS score of 1 or less during the 28 days before the final dose, compared to 3.1% in the placebo arm. Another study, NCT02655237, reported that 82.2% of participants in the Relugolix 40 mg arm achieved a total PBAC score of less than 10 from Week 6 to 12, while 83.1% did so in the Leuprorelin 1.88 mg or 3.75 mg arm.

Further leiomyoma studies focused on menstrual blood loss (MBL). In NCT03049735, 73.4% of participants in the Relugolix Plus E2/NETA arm achieved an MBL volume of less than 80 mL and a 50% or greater reduction from baseline MBL volume, compared to 18.9% in the placebo arm. Similarly, NCT03103087 showed that 71.2% of participants in the Relugolix Plus E2/NETA arm met these MBL criteria, versus 14.73% in the placebo arm. At Week 52 in NCT03412890, 86.50% of participants in the Relugolix Plus E2/NETA arm achieved or maintained an MBL volume of less than 80 mL and at least a 50% reduction from baseline MBL volume. In the same study, 79.87% in the Relugolix Plus Delayed E2/NETA arm and 75.00% in the placebo arm met these criteria.

For prostatic neoplasms, the HERO study (NCT03085095) reported a sustained castration rate of 96.7% for participants in the Relugolix arm, compared to 88.8% in the Leuprolide Acetate arm, from Week 5 Day 1 to Week 49 Day 1. In endometriosis, NCT03654274 assessed dysmenorrhea responder criteria. At Week 52, 84.8% of participants in the Relugolix Plus E2/NETA arm met these criteria, compared to 82.2% in the Relugolix Plus Delayed E2/NETA arm and 75.6% in the placebo arm. At Week 104 in the same study, 84.8% of participants in the Relugolix Plus E2/NETA arm met the dysmenorrhea responder criteria, with 83.0% in the Relugolix Plus Delayed E2/NETA arm and 80.4% in the placebo arm. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Relugolix publications (54)

2026 (2 papers)

  1. Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.
    Patel SA, Yadalam AK, van Assen M, et al. · JAMA Cardiol · 2026 · Derived
    PubMed: PMID 41706486 · NCT05320406 (REVELUTION) · Prostatic Neoplasms
  2. Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.
    Loper M, Qadar A, Vesely SK, et al. · BMJ Open · 2026 · Derived
    PubMed: PMID 42031503 · NCT06130995 · Neoplasm, Residual

2025 (3 papers)

  1. Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration.
    Freedland SJ, Ramaswamy K, Kavati A, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 41174189 · NCT06462014 · Prostatic Neoplasms
  2. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
    De La Cerda J, Belkoff L, Courtney KD, et al. · Target Oncol · 2025 · Derived
    PubMed: PMID 40180682 · NCT04666129
  3. Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2.
    Catherino WH, Al-Hendy A, Zaim S, et al. · Fertil Steril · 2025 · Derived
    PubMed: PMID 40320117 · NCT03103087 · Leiomyoma

2024 (8 papers)

  1. A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd And mRi study.
    Ciccarone F, Biscione A, Robba E, et al. · Am J Obstet Gynecol · 2024 · Trial result
    PubMed: PMID 39084498 · NCT06953076 (MySaturn) · Leiomyoma
  2. A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy.
    Stewart EA, Lukes AS, Venturella R, et al. · Pain Manag · 2024 · Derived
    PubMed: PMID 39466126 · NCT03049735 · Leiomyoma
  3. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA, Al-Hendy A, Lukes AS, et al. · Am J Obstet Gynecol · 2024 · Derived
    PubMed: PMID 37863160 · NCT03049735 · Leiomyoma
  4. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
    Spratt DE, Dorff T, McKay RR, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 38488039 · NCT05467176 (OPTYX) · Prostatic Neoplasms
  5. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    Shore N, Hafron J, Saltzstein D, et al. · J Urol · 2024 · Derived
    PubMed: PMID 39088398 · NCT04523207 · Prostatic Neoplasms
  6. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    Morgan TM, Boorjian SA, Buyyounouski MK, et al. · J Urol · 2024 · Derived
    PubMed: PMID 38421243 · NCT04423211 · Prostatic Neoplasms
  7. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
    Becker CM, Johnson NP, As-Sanie S, et al. · Hum Reprod · 2024 · Derived
    PubMed: PMID 38243752 · NCT03654274 · Endometriosis
  8. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
    As-Sanie S, Abrao MS, Reznichenko G, et al. · Fertil Steril · 2024 · Derived
    PubMed: PMID 38906210 · NCT03654274 · Endometriosis

2023 (11 papers)

  1. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. · Am J Obstet Gynecol · 2023 · Trial result
    PubMed: PMID 37666383 · NCT06953076 (MySaturn) · Leiomyoma
  2. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
    Shore ND, Mehlhaff BA, Cookson MS, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 37713020 · NCT03085095 (HERO) · Prostatic Neoplasms
  3. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
    Neblett MF, Stewart EA · Obstet Gynecol · 2023 · Derived
    PubMed: PMID 37103532 · NCT04756037 (SERENE) · Leiomyoma
  4. A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women.
    Lukes A, Migoya E, Johnson B, et al. · Clin Pharmacokinet · 2023 · Derived
    PubMed: PMID 37365436 · NCT04978688
  5. Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study.
    Hunsche E, Gauthier M, Witherspoon B, et al. · Int J Womens Health · 2023 · Derived
    PubMed: PMID 37283994 · NCT03204331 · Endometriosis
  6. A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
    Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. · Pain Manag · 2023 · Derived
    PubMed: PMID 37982388 · NCT03204318 · Endometriosis
  7. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
    De La Cerda J, Dunshee C, Gervasi L, et al. · Target Oncol · 2023 · Derived
    PubMed: PMID 37060432 · NCT04666129
  8. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G, Belkoff L, Hafron JM, et al. · Target Oncol · 2023 · Derived
    PubMed: PMID 36472728 · NCT04523207 · Prostatic Neoplasms
  9. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.
    Al-Hendy A, Lukes AS, Venturella R, et al. · J Comp Eff Res · 2023 · Derived
    PubMed: PMID 37477173 · NCT03049735 · Leiomyoma
  10. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
    Al-Hendy A, Lukes AS, Poindexter AN, et al. · Pain Manag · 2023 · Derived
    PubMed: PMID 37183454 · NCT03049735 · Leiomyoma
  11. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition.
    Basit A, Amory JK, Mettu VS, et al. · Drug Metab Dispos · 2023 · Background
    PubMed: PMID 36623880 · NCT06312761 (OralT12) · Eunuchism

2022 (8 papers)

  1. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
    Al-Hendy A, Lukes AS, Poindexter AN, et al. · Obstet Gynecol · 2022 · Trial result
    PubMed: PMID 36357960 · NCT06953076 (MySaturn) · Leiomyoma
  2. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
    Stewart EA, Lukes AS, Venturella R, et al. · Obstet Gynecol · 2022 · Derived
    PubMed: PMID 35675604 · NCT03103087 · Leiomyoma
  3. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
    Shore ND, Sutton J · Future Oncol · 2022 · Derived
    PubMed: PMID 35587650 · NCT03085095 (HERO) · Prostatic Neoplasms
  4. The Burden of Uterine Fibroids from the Perspective of US Women Participating in Open-Ended Interviews.
    Hunsche E, Rakov V, Scippa K, et al. · Womens Health Rep (New Rochelle) · 2022 · Derived
    PubMed: PMID 35415708 · NCT03103087 · Leiomyoma
  5. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. · Lancet · 2022 · Derived
    PubMed: PMID 35717987 · NCT03204331 · Endometriosis
  6. Testosterone Replacement Therapy in Hypogonadal Men.
    Wang C, Swerdloff RS · Endocrinol Metab Clin North Am · 2022 · Background
    PubMed: PMID 35216722 · NCT06312761 (OralT12) · Eunuchism
  7. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men.
    Swerdloff RS, Dudley RE · Ther Adv Urol · 2022 · Background
    PubMed: PMID 32655691 · NCT06312761 (OralT12) · Eunuchism
  8. Cortical mechanisms of visual hypersensitivity in women at risk for chronic pelvic pain.
    Kmiecik MJ, Tu FF, Silton RL, et al. · Pain · 2022 · Background
    PubMed: PMID 34510138 · NCT06279195 · Pelvic Pain

2021 (1 paper)

  1. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A, Lukes AS, Poindexter AN, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 33596357 · NCT06953076 (MySaturn) · Leiomyoma

2020 (3 papers)

  1. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment.
    Rolla E · F1000Res · 2020 · Derived
    PubMed: PMID 31069056 · NCT03204318 · Endometriosis
  2. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
    Osuga Y, Enya K, Kudou K, et al. · Fertil Steril · 2020 · Derived
    PubMed: PMID 31594635 · NCT02655224 · Leiomyoma
  3. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND, Saad F, Cookson MS, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32469183 · NCT03085095 (HERO) · Prostatic Neoplasms

2019 (1 paper)

  1. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y, Enya K, Kudou K, et al. · Obstet Gynecol · 2019 · Derived
    PubMed: PMID 30741797 · NCT02655237 · Leiomyoma

2018 (2 papers)

  1. Cine MRI during spontaneous cramps in women with menstrual pain.
    Hellman KM, Kuhn CS, Tu FF, et al. · Am J Obstet Gynecol · 2018 · Background
    PubMed: PMID 29409786 · NCT06279195 · Pelvic Pain
  2. Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.
    Bhatt DK, Basit A, Zhang H, et al. · Drug Metab Dispos · 2018 · Background
    PubMed: PMID 29602798 · NCT06312761 (OralT12) · Eunuchism

2017 (1 paper)

  1. Uterine Fibroids: Diagnosis and Treatment.
    De La Cruz MS, Buchanan EM · Am Fam Physician · 2017 · Trial result
    PubMed: PMID 28084714 · NCT06953076 (MySaturn) · Leiomyoma

2016 (2 papers)

  1. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group.
    Van den Bosch T, Dueholm M, Leone FP, et al. · Ultrasound Obstet Gynecol · 2016 · Trial result
    PubMed: PMID 25652685 · NCT06953076 (MySaturn) · Leiomyoma
  2. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
    MacLean DB, Shi H, Faessel HM, et al. · J Clin Endocrinol Metab · 2016 · Background
    PubMed: PMID 26502357 · NCT06312761 (OralT12) · Eunuchism

2009 (1 paper)

  1. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies.
    de Ronde W · Hum Reprod · 2009 · Background
    PubMed: PMID 18948313 · NCT06312761 (OralT12) · Eunuchism

2006 (1 paper)

  1. Minimum training recommendations for the practice of medical ultrasound.
    Education and Practical Standards Committee, European Federation of Societies for Ultrasound in Medicine and Biology · Ultraschall Med · 2006 · Trial result
    PubMed: PMID 16508866 · NCT06953076 (MySaturn) · Leiomyoma

2005 (1 paper)

  1. The therapeutic potential of testosterone patches.
    Amory JK, Matsumoto AM · Expert Opin Investig Drugs · 2005 · Background
    PubMed: PMID 15991940 · NCT06312761 (OralT12) · Eunuchism

2001 (1 paper)

  1. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS, Wang C, Cunningham G, et al. · J Clin Endocrinol Metab · 2001 · Background
    PubMed: PMID 11134099 · NCT06312761 (OralT12) · Eunuchism

2000 (1 paper)

  1. Androgen replacement and quality of life in patients treated for bilateral testicular cancer.
    Fosså SD, Opjordsmoen S, Haug E, et al. · Eur J Cancer · 2000 · Background
    PubMed: PMID 10615233 · NCT06312761 (OralT12) · Eunuchism

1997 (3 papers)

  1. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
    Katznelson L, Finkelstein JS, Schoenfeld DA, et al. · J Clin Endocrinol Metab · 1997 · Background
    PubMed: PMID 8954042 · NCT06312761 (OralT12) · Eunuchism
  2. Clinical review 85: Emerging issues in androgen replacement therapy.
    Bhasin S, Bremner WJ · J Clin Endocrinol Metab · 1997 · Background
    PubMed: PMID 8989221 · NCT06312761 (OralT12) · Eunuchism
  3. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
    Behre HM, Kliesch S, Leifke E, et al. · J Clin Endocrinol Metab · 1997 · Background
    PubMed: PMID 9253305 · NCT06312761 (OralT12) · Eunuchism

1996 (2 papers)

  1. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study.
    Wang C, Alexander G, Berman N, et al. · J Clin Endocrinol Metab · 1996 · Background
    PubMed: PMID 8855804 · NCT06312761 (OralT12) · Eunuchism
  2. Androgens in men--uses and abuses.
    Bagatell CJ, Bremner WJ · N Engl J Med · 1996 · Background
    PubMed: PMID 8594431 · NCT06312761 (OralT12) · Eunuchism

1974 (1 paper)

  1. Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin.
    Weinstein RL, Kelch RP, Jenner MR, et al. · J Clin Invest · 1974 · Background
    PubMed: PMID 4271572 · NCT06312761 (OralT12) · Eunuchism

1972 (1 paper)

  1. Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome.
    Kelch RP, Jenner MR, Weinstein R, et al. · J Clin Invest · 1972 · Background
    PubMed: PMID 4259253 · NCT06312761 (OralT12) · Eunuchism

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).